Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urinary Bladder Overactive Clear all
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

NCT04211831
View directory record Official record
Conditions
Overactive Bladder With Urge Urinary Incontinence
Interventions
URO-902, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
40 Years to 79 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841
View directory record Official record
Conditions
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)

NCT01502956
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
InterStim® device, Botox® injection
Device · Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 10, 2026, 4:15 AM EDT
Completed No phase listed Observational

The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections

NCT04479709
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
60 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 10, 2026, 4:15 AM EDT
Completed No phase listed Observational

Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

NCT03043287
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Shreveport, Louisiana • Baltimore, Maryland • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 10, 2026, 4:15 AM EDT
Recruiting Not applicable Interventional

BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder

NCT04873037
View directory record Official record
Conditions
Overactive Bladder Syndrome, Overactive Bladder, Urinary Frequency, Urinary Urgency
Interventions
BTL Emsella Chair, Sham BTL Emsella Chair
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 10, 2026, 4:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

NCT05519072
View directory record Official record
Conditions
Antibiotic Prophylaxis
Interventions
Nitrofurantoin
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

NCT03817931
View directory record Official record
Conditions
Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions
Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
Drug · Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 10, 2026, 4:15 AM EDT
Completed No phase listed Observational Results available

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions
Intra-detrusor injection of Onabotulinumtoxin-A
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 10, 2026, 4:15 AM EDT
Not listed No phase listed Observational

Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study

NCT04853849
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Pelvic Floor Disorders
Interventions
Not listed
Lead sponsor
Renalis
Industry
Eligibility
40 Years and older · Female only
Enrollment
50 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910520
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

Mirabegron and Urinary Urgency Incontinence

NCT02495389
View directory record Official record
Conditions
Overactive Bladder
Interventions
Mirabegron
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 10, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair

NCT02502838
View directory record Official record
Conditions
Overactive Bladder, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
22 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 10, 2026, 4:15 AM EDT
Completed No phase listed Observational

In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder

NCT04155593
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 10, 2026, 4:15 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

BlueWind RENOVA iStim™ System for the Treatment of OAB

NCT03596671
View directory record Official record
Conditions
Treatment of Patients Suffering From Overactive Bladder (OAB)
Interventions
RENOVA iStim™ System
Device
Lead sponsor
BlueWind Medical
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Orange, California • San Diego, California • Norwalk, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 10, 2026, 4:15 AM EDT
Recruiting Not applicable Interventional

Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

NCT06944392
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Pumpkin Seed Extract
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Behavioral Treatment of Overactive Bladder in Men

NCT01187498
View directory record Official record
Conditions
Overactive Bladder
Interventions
Behavioral training, Oxybutynin chloride, extended-release
Behavioral · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years and older · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 10, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

NCT00220389
View directory record Official record
Conditions
Overactive Bladder
Interventions
SPM 907
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Timeline
2003 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Sep 10, 2026, 4:15 AM EDT
Terminated Not applicable Interventional Results available

PTNS for Female Patients Suffering From Multiple Sclerosis

NCT05422625
View directory record Official record
Conditions
Multiple Sclerosis, Overactive Bladder
Interventions
PTNS Treatment, Sham PTNS Treatment
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 10, 2026, 4:15 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

NCT07227285
View directory record Official record
Conditions
Urinary Bladder, Overactive, Spinal Cord Injury
Interventions
Urodynamics, EG110A, Patient-reported Outcome
Other · Drug
Lead sponsor
Cyllene Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Downey, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 10, 2026, 4:15 AM EDT